Effect of Adding Losartan to Bevacizumab for Treating Diabetic Macular Edema
المؤلفون المشاركون
Ghassemi, Fariba
Yasemi, Masoud
Amini, Abdulrahim
Nabavi, Amin
Johari, Mohammadkarim
المصدر
العدد
المجلد 2020، العدد 2020 (31 ديسمبر/كانون الأول 2020)، ص ص. 1-5، 5ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2020-10-01
دولة النشر
مصر
عدد الصفحات
5
التخصصات الرئيسية
الملخص EN
Introduction.
Diabetic retinopathy is the most common cause of visual loss and blindness in the age group of 20 to 64 years.
This study aimed to evaluate the efficacy of oral Losartan adjuvant therapy in combination with intravitreal injection of Bevacizumab in the treatment of diabetic macular edema.
Methods.
In this randomized clinical trial, 61 eyes of 47 patients with normal blood pressure and diabetic macular edema and nonproliferative diabetic retinopathy were studied.
Patients were randomly divided into Losartan (n = 33) and control (n = 28) groups.
All patients received 3–6 intravitreal injections of Bevacizumab over 6 months.
General examination including blood pressure and glycosylated hemoglobin measurements were performed in all patients.
Complete ophthalmologic examination and macular OCT were performed at the first, third, and sixth months of treatment in all patients.
Results.
The mean age of the patients studied was 57.1 ± 7.4 years and 37.7% of the patients were male.
There was no significant difference between the two groups in terms of initial visual acuity, central macular thickness, and frequency of injections.
There was no significant difference in visual acuity and central macular thickness between the two groups at the first, third, and sixth months of treatment.
Age, frequency of injection, and initial macular thickness less than 450 microns were effective in patients’ final visual acuity.
Conclusion.
Short-term adjuvant treatment with Losartan in patients with diabetic macular edema and nonproliferative diabetic retinopathy has no greater effect than the standard treatment.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Ghassemi, Fariba& Amini, Abdulrahim& Yasemi, Masoud& Nabavi, Amin& Johari, Mohammadkarim. 2020. Effect of Adding Losartan to Bevacizumab for Treating Diabetic Macular Edema. Journal of Ophthalmology،Vol. 2020, no. 2020, pp.1-5.
https://search.emarefa.net/detail/BIM-1189401
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Ghassemi, Fariba…[et al.]. Effect of Adding Losartan to Bevacizumab for Treating Diabetic Macular Edema. Journal of Ophthalmology No. 2020 (2020), pp.1-5.
https://search.emarefa.net/detail/BIM-1189401
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Ghassemi, Fariba& Amini, Abdulrahim& Yasemi, Masoud& Nabavi, Amin& Johari, Mohammadkarim. Effect of Adding Losartan to Bevacizumab for Treating Diabetic Macular Edema. Journal of Ophthalmology. 2020. Vol. 2020, no. 2020, pp.1-5.
https://search.emarefa.net/detail/BIM-1189401
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1189401
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر